# Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

> **NCT07478848** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 14 (estimated)

## Conditions studied

- Large B Cell Lymphoma
- Non Hodgkin Lymphoma (NHL)
- Diffuse Large B Cell Lymphoma (DLBCL)
- Diffuse Large B Cell Lymphoma Refractory
- Diffuse Large B Cell Lymphoma Relapsed

## Interventions

- **DRUG:** Vancomycin 125mg

## Key facts

- **NCT ID:** NCT07478848
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07478848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07478848, "Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07478848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*